Aroa Biosurgery Seeks ASX Quotation for New Shares Issued Under Employee Incentive Scheme

An announcement from Aroa Biosurgery Ltd ( (AU:ARX) ) is now available.

Aroa Biosurgery Limited has applied for quotation on the ASX of 442,961 new fully paid ordinary shares issued on 29 January 2026 under an employee incentive scheme. The additional securities, to trade under the company’s existing ARX ticker, modestly increase the company’s free float and reflect the ongoing use of equity-based remuneration to retain and incentivise staff, with limited immediate impact on capital structure but signalling continued commitment to employee alignment with shareholder interests.

The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

More about Aroa Biosurgery Ltd

Aroa Biosurgery Limited is a medical technology company listed on the ASX under the code ARX, operating in the biosurgery and advanced wound care sector. It develops and commercialises biologically derived products used in surgical and soft-tissue repair, targeting hospitals, surgeons and healthcare providers in markets where demand is growing for regenerative tissue and wound management solutions.

Average Trading Volume: 209,546

Technical Sentiment Signal: Sell

Current Market Cap: A$215.6M

Find detailed analytics on ARX stock on TipRanks’ Stock Analysis page.